Reproducibility and biological variability of HDL's vascular functional assays

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 588-594

  O'Neill, Francis ^a   McLoughlin, Eve ^a   Riwanto, Meliana ^b   Manz, Jasmin ^b   Adler, Andreas ^a   Sutill, Emma ^a   Khan, Tauseef ^a   Haywood, Rachel ^a   Kay, Christopher W M ^a   D'Aiuto, Francesco ^a   Charakida, Marietta ^a   Landmesser, Ulf ^b   Deanfield, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

High Denisty Lipoprotein; Methodology; Vascular Function

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; SUPEROXIDE; TRIACYLGLYCEROL; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL FUNCTION; BODY MASS; CARDIOVASCULAR RISK; CELL ASSAY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HIGH DENSITY LIPOPROTEIN FUNCTIONAL ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID ANALYSIS; MALE; MIDDLE AGED; NONHUMAN; PERIODONTITIS; PRIORITY JOURNAL; REPRODUCIBILITY; ANIMAL; ANTHROPOMETRY; AORTA; BLOOD; BLOOD ANALYSIS; BOVINE; CARDIOVASCULAR DISEASE; CHEMISTRY; CLINICAL TRIAL (TOPIC); CYTOLOGY; METABOLISM; NORMAL HUMAN; PATHOLOGY; YOUNG ADULT;

ADULT; ANIMALS; ANTHROPOMETRY; AORTA; ARYLDIALKYLPHOSPHATASE; BLOOD CHEMICAL ANALYSIS; CARDIOVASCULAR DISEASES; CATTLE; CLINICAL TRIALS AS TOPIC; ENDOTHELIAL CELLS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LIPOPROTEINS, HDL; MALE; NITRIC OXIDE; PERIODONTITIS; REPRODUCIBILITY OF RESULTS; SUPEROXIDES; YOUNG ADULT;

EID: 84934992975     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.005     Document Type: Article

References (29)

1. World Health Organization Global Status Report on Noncommunicable Diseases 2011.
2. Di A.E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., Wood A.M., Lewington S., Sattar N., Packard C.J., Collins R., Thompson S.G., Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302(18):1993-2000.
3. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., Lopez-Sendon J., Mosca L., Tardif J.C., Waters D.D., Shear C.L., Revkin J.H., Buhr K.A., Fisher M.R., Tall A.R., Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N.Engl. J. Med. 2007, 357(21):2109-2122.
4. Schwartz G.G., Olsson A.G., Abt M., Ballantyne C.M., Barter P.J., Brumm J., Chaitman B.R., Holme I.M., Kallend D., Leiter L.A., Leitersdorf E., McMurray J.J., Mundl H., Nicholls S.J., Shah P.K., Tardif J.C., Wright R.S. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N.Engl. J. Med. 2012, 367(22):2089-2099.
5. Riwanto M., Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J.Lipid Res. 2013, 54(12):3227-3243.
6. Rosenson R.S., Brewer H.B., Davidson W.S., Fayad Z.A., Fuster V., Goldstein J., Hellerstein M., Jiang X.C., Phillips M.C., Rader D.J., Remaley A.T., Rothblat G.H., Tall A.R., Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012, 125(15):1905-1919.
7. Annema W., von E.A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ. J. 2013, 77(10):2432-2448.
8. Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D.M., Chroni A., Yonekawa K., Stein S., Schaefer N., Mueller M., Akhmedov A., Daniil G., Manes C., Templin C., Wyss C., Maier W., Tanner F.C., Matter C.M., Corti R., Furlong C., Lusis A.J., von E.A., Fogelman A.M., Luscher T.F., Landmesser U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J.Clin. Invest. 2011, 121(7):2693-2708.
9. Charakida M., Besler C., Batuca J.R., Sangle S., Marques S., Sousa M., Wang G., Tousoulis D., Delgado A.J., Loukogeorgakis S.P., Mackworth-Young C., D'Cruz D., Luscher T., Landmesser U., Deanfield J.E. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009, 302(11):1210-1217.
10. Sorrentino S.A., Besler C., Rohrer L., Meyer M., Heinrich K., Bahlmann F.H., Mueller M., Horvath T., Doerries C., Heinemann M., Flemmer S., Markowski A., Manes C., Bahr M.J., Haller H., von E.A., Drexler H., Landmesser U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010, 121(1):110-122.
11. O'Neill F., Riwanto M., Charakida M., Colin S., Manz J., McLoughlin E., Khan T., Klein N., Kay C.W.M., Patel K., Chinetti G., Staels B., D'Aiuto F., Landmesser U., Deanfield J. Structural and functional changes in HDL with low grade and chronic inflammation. Int. J. Cardiol. 2015 Jun 1, 188:111-116. Epub 2015 Mar 5. 10.1016/j.ijcard.2015.03.058.
12. Tong H., Knapp H.R., VanRollins M. Alow temperature flotation method to rapidly isolate lipoproteins from plasma. J.Lipid Res. 1998, 39(8):1696-1704.
13. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299(11):1265-1276.
14. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1(8476):307-310.
15. Khera A.V., Cuchel M., Llera-Moya M., Rodrigues A., Burke M.F., Jafri K., French B.C., Phillips J.A., Mucksavage M.L., Wilensky R.L., Mohler E.R., Rothblat G.H., Rader D.J. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N.Engl. J. Med. 2011, 364(2):127-135.
16. Rohatgi A., Khera A., Berry J.D., Givens E.G., Ayers C.R., Wedin K.E., Neeland I.J., Yuhanna I.S., Rader D.R., de Lemos J.A., Shaul P.W. HDL cholesterol efflux capacity and incident cardiovascular events. N.Engl. J. Med. 2014, 371(25):2383-2393.
17. Li X.M., Tang W.H., Mosior M.K., Huang Y., Wu Y., Matter W., Gao V., Schmitt D., Didonato J.A., Fisher E.A., Smith J.D., Hazen S.L. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler. Thromb. Vasc. Biol. 2013, 33(7):1696-1705.
18. Khera A.V., Patel P.J., Reilly M.P., Rader D.J. The Addition of Niacin to Statin Therapy Improves High-Density Lipoprotein Cholesterol Levels but not Metrics of Functionality 2013, 61 ed.
19. Holy E.W., Besler C., Reiner M.F., Camici G.G., Manz J., Beer J.H., Luscher T.F., Landmesser U., Tanner F.C. High-density lipoprotein from patients with coronary heart disease loses anti-thrombotic effects on endothelial cells: impact on arterial thrombus formation. Thromb. Haemost. 2014, 112(5):1024-1035.
20. Speer T., Rohrer L., Blyszczuk P., Shroff R., Kuschnerus K., Krankel N., Kania G., Zewinger S., Akhmedov A., Shi Y., Martin T., Perisa D., Winnik S., Muller M.F., Sester U., Wernicke G., Jung A., Gutteck U., Eriksson U., Geisel J., Deanfield J., von E.A., Luscher T.F., Fliser D., Bahlmann F.H., Landmesser U. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 2013, 38(4):754-768.
21. Berg K., Ericsson M., Lindgren M., Gustafsson H. Ahigh precision method for quantitative measurements of reactive oxygen species in frozen biopsies. PLoS One 2014, 9(3):e90964.
22. Garelnabi M., Younis A. Paraoxonase-1 enzyme activity assay for clinical samples: validation and correlation studies. Med. Sci. Monit. 2015, 21:902-908.
23. Leikert J.F., Rathel T.R., Muller C., Vollmar A.M., Dirsch V.M. Reliable invitro measurement of nitric oxide released from endothelial cells using low concentrations of the fluorescent probe 4,5-diaminofluorescein. FEBS Lett. 2001, 506(2):131-134.
24. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., Marcel Y.L., Anderson R.G., Mendelsohn M.E., Hobbs H.H., Shaul P.W. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 2001, 7(7):853-857.
25. Karuna R., Park R., Othman A., Holleboom A.G., Motazacker M.M., Sutter I., Kuivenhoven J.A., Rohrer L., Matile H., Hornemann T., Stoffel M., Rentsch K.M., von E.A. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 2011, 219(2):855-863.
26. Rodriguez C., Gonzalez-Diez M., Badimon L., Martinez-Gonzalez J. Sphingosine-1-phosphate: a bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb. Haemost. 2009, 101(4):665-673.
27. Kunitake S.T., Kane J.P. Factors affecting the integrity of high density lipoproteins in the ultracentrifuge. J.Lipid Res. 1982, 23(6):936-940.
28. Rathel T.R., Leikert J.J., Vollmar A.M., Dirsch V.M. Application of 4,5-diaminofluorescein to reliably measure nitric oxide released from endothelial cells invitro. Biol. Proced. Online 2003, 5:136-142.
29. Ye X., Kim W.S., Rubakhin S.S., Sweedler J.V. Measurement of nitric oxide by 4,5-diaminofluorescein without interferences. Analyst 2004, 129(12):1200-1205.